ProQR Therapeutics NV is a biopharmaceutical company... Show more
ProQR Therapeutics N.V. (PRQR) is a biotechnology company focused on discovering and developing novel RNA-based medicines for severe genetic diseases. Investors follow the company primarily for its Axiomer RNA editing technology platform, which is designed to correct or modulate gene expression at the RNA level rather than permanently altering DNA. Because ProQR is clinical-stage and does not yet market approved products, its financial profile is characterized by research spending and collaboration revenue rather than product sales.
ProQR Therapeutics was founded in 2012 by Daniel de Boer, Gerard Platenburg, the late Henri Termeer, and Dinko Valerio. The company is incorporated under Dutch law and has its statutory seat and headquarters in Leiden, the Netherlands, at Zernikedreef 9. Its ordinary shares began trading on Nasdaq in September 2014 and are listed on the Nasdaq Capital Market under the symbol PRQR.
The company operates a single reportable segment: the discovery and development of RNA-based therapeutics. Its core technology, Axiomer, uses short, engineered oligonucleotides (EONs) to recruit naturally occurring enzymes called ADARs to make precise edits in messenger RNA (mRNA). These edits can correct disease-causing mutations, modulate protein levels, or introduce protective changes. Because Axiomer acts on RNA rather than DNA, any effects are designed to be transient and reversible, which the company positions as a potential safety advantage over permanent gene-editing approaches.
ProQR's lead Axiomer program, AX-0810, targets NTCP for the treatment of cholestatic diseases, conditions marked by a toxic buildup of bile acids in the liver. The company's broader pipeline includes programs aimed at Rett syndrome, metabolic dysfunction-associated steatohepatitis (MASH), and cardiovascular disease. Historically, the company also worked on RNA therapies for rare inherited retinal diseases such as Leber congenital amaurosis type 10.
Because ProQR has no approved commercial products, its primary revenue sources are collaboration and licensing agreements. The most significant is a global research and licensing collaboration with LLY (Eli Lilly and Company), first announced in 2021 and later expanded, under which the two companies use the Axiomer platform to pursue targets in the liver and nervous system. Under that agreement, ProQR receives upfront and milestone payments and is eligible for royalties on any resulting products.
Investor interest in PRQR centers on the long-term potential of RNA editing as a new therapeutic modality. Unlike some competing RNA-interference approaches that mainly reduce gene expression, Axiomer is designed to correct or modulate specific targets, potentially broadening the range of diseases it can address. The collaboration with a major pharmaceutical partner such as Eli Lilly also lends external validation and non-dilutive funding potential, while the company's focus on rare and underserved diseases offers the possibility of significant unmet medical need if clinical programs succeed.
The company's market position is that of an emerging platform biotechnology firm competing against both established RNA-therapeutics companies and newer gene-editing developers. Its differentiation rests on the specificity and reversibility of its RNA-editing approach and its ability to adapt the platform across multiple therapeutic areas.
As a clinical-stage biotechnology company, ProQR carries substantial risk. Its drug candidates must still demonstrate safety and efficacy in clinical trials and secure regulatory approval, a process with high failure rates. The company has historically reported operating losses and relies on collaboration revenue, equity offerings, and other financing to fund research. Additional risks include competition in the fast-moving RNA and genetic-medicine field, dependence on its collaboration with Eli Lilly, and the inherent uncertainty of translating preclinical results into approved therapies. Investors should also note that, as a Dutch-domiciled company reporting under IFRS, its financial profile may differ from U.S.-incorporated peers.
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. Whether you are researching biotechnology names like PRQR or exploring other sectors, the AI Screener offers a structured way to narrow the universe of potential opportunities.
ProQR Therapeutics is a clinical-stage biotechnology company distinguished by its Axiomer RNA editing platform and its focus on genetically driven diseases with limited treatment options. Its market position is built on a differentiated scientific approach and a high-profile collaboration with Eli Lilly, yet it remains subject to the considerable risks common to early-stage drug development. For investors, PRQR represents a speculative, innovation-driven profile in the genetic-medicine space rather than a revenue-generating commercial business.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a biopharmaceutical company with interest in the discovery and development of therapeutics for the treatment of genetic disorders
Industry Biotechnology